Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Rocket Pharmaceuticals due to misleading statements regarding the safety of its clinical trial for RP-A501, which led to significant investor losses [2][4][5]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi is encouraging investors who suffered losses exceeding $50,000 in Rocket Pharmaceuticals between February 27, 2025, and May 26, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against Rocket Pharmaceuticals, with a deadline of August 11, 2025, for investors to seek the role of lead plaintiff [2][7]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [3]. Group 2: Allegations Against Rocket Pharmaceuticals - The complaint alleges that Rocket Pharmaceuticals provided overly positive statements while concealing material adverse facts about the safety of RP-A501 and the clinical trial protocol [4]. - It was revealed that Rocket amended the trial protocol to include a new immunomodulatory agent without informing shareholders, which contributed to artificially inflated stock prices [4]. - Following the announcement of a clinical hold by the FDA due to a Serious Adverse Event, including a patient death, Rocket's stock price plummeted from $6.27 to $2.33, a decline of approximately 37% in one trading day [5][6]. Group 3: Investor Communication and Whistleblower Encouragement - Faruqi & Faruqi is also seeking information from whistleblowers, former employees, and shareholders regarding Rocket's conduct [8].

Core Viewpoint - A class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. for allegedly providing misleading information regarding the safety and clinical trial protocol of its RP-A501 treatment, leading to significant financial losses for investors [1][3]. Summary by Sections Lawsuit Details - The lawsuit is on behalf of all individuals and entities who purchased Rocket securities between February 27, 2025, and May 26, 2025, with a deadline of August 11, 2025, for investors to apply as lead plaintiffs [1]. - The complaint alleges that Rocket made positive statements while concealing serious risks, including the occurrence of Serious Adverse Events (SAEs) during clinical trials [3]. Clinical Trial Issues - Rocket amended the trial protocol to include a new immunomodulatory agent without informing shareholders, which is claimed to have misled investors about the safety of the treatment [3]. - On May 27, 2025, the FDA placed a clinical hold on the RP-A501 Phase 2 study after a patient suffered a SAE, which included death, following the undisclosed protocol amendment [4]. Stock Price Impact - Following the announcement of the clinical hold, Rocket's stock price plummeted from $6.27 per share on May 23, 2025, to $2.33 per share on May 27, 2025, marking a decline of approximately 37% in one trading day [5].

Core Viewpoint - Robbins LLP has initiated a class action lawsuit on behalf of investors who acquired Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) securities between February 7, 2025, and May 26, 2025, due to allegations of misleading information regarding the company's clinical trial for RP-A501 [1][2]. Group 1: Allegations and Company Actions - The lawsuit claims that Rocket Pharmaceuticals misrepresented the viability and efficacy of RP-A501, particularly regarding the timeline and safety of its Phase 2 pivotal trial for Danon disease [2]. - It is alleged that the company provided an overly optimistic outlook on the trial's progress, which was contradicted by the reality of a Serious Adverse Event (SAE) that resulted in a patient's death after protocol amendments were made [2]. - Following the announcement of the SAE on May 27, 2025, Rocket's stock price plummeted from $6.27 per share on May 23, 2025, to $2.33 per share [3]. Group 2: Class Action Participation - Shareholders interested in participating in the class action can contact Robbins LLP to serve as lead plaintiff, representing other class members in the litigation [4]. - Shareholders are not required to take action to be eligible for recovery and can remain absent class members if they choose [4]. Group 3: Company Background - Robbins LLP has been a leader in shareholder rights litigation since 2002, focusing on helping shareholders recover losses and improve corporate governance [5].

NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. (“Rocket” or “the Company”) (NASDAQ: RCKT) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Ro ...

NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (NASDAQ: RCKT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Rocket investors who were adversely affected by alleged securities fraud between February 27, 2025 and May 26, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/rocket-pharmaceuti ...

RCKT Investors with Losses Encouraged to Contact the FirmSAN FRANCISCO, June 13, 2025 /PRNewswire/ -- A securities class action lawsuit styled Ho v. Rocket Pharmaceuticals, Inc., et al., No. 3:25-cv-10049 (D. N.J.) has been filed and seeks to represent investors who purchased or otherwise acquired Rocket Pharmaceuticals securities between February 27, 2025 and May 26, 2025.The lawsuit comes after investors saw the price of their shares in Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) crash over 60% on May 27, ...

NEW YORK, June 13, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (NASDAQ: RCKT) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Rocket investors who were adversely affected by alleged securities fraud between February 27, 2025 and May 26, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/rocket-pharmaceuticals-i ...

SAN DIEGO, June 13, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) securities between February 27, 2025 and May 26, 2025, inclusive (the “Class Period”), have until August 11, 2025 to seek appointment as lead plaintiff of the Rocket Pharmaceuticals class action lawsuit. Captioned Ho v. Rocket Pharmaceuticals, Inc., No. 25-cv-10049 (D.N.J.), the Rocket Pharmaceuticals class action lawsuit charges ...

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of Rocket Pharmaceuticals securities during the specified Class Period, alleging misleading statements regarding the safety and clinical trial protocol of RP-A501 [1][5]. Group 1: Lawsuit Details - The class action lawsuit pertains to securities purchased between February 27, 2025, and May 26, 2025 [1]. - The lawsuit claims that Rocket Pharmaceuticals provided positive statements while concealing material adverse facts, including the risk of Serious Adverse Events (SAEs) and participant deaths in clinical trials [5]. - The firm amended the trial's protocol without informing shareholders, leading to artificially inflated stock prices [5]. Group 2: Investor Participation - Investors who purchased Rocket Pharmaceuticals securities during the Class Period may be entitled to compensation without upfront costs through a contingency fee arrangement [2]. - Interested investors can join the class action by submitting a form or contacting the law firm directly [3][6]. - A lead plaintiff must be appointed by August 11, 2025, to represent other class members in the litigation [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company at the time [4]. - The firm has consistently ranked among the top firms for securities class action settlements since 2013, recovering hundreds of millions for investors [4]. - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in representing shareholder interests [4].

Core Viewpoint - Rocket Pharmaceuticals, Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, related to misleading statements about its clinical trial for RP-A501, which resulted in serious adverse events, including patient death [1][4][5]. Company Overview - Rocket Pharmaceuticals operates as a late-stage biotechnology company focused on developing gene therapies for rare and devastating diseases [3]. Allegations of the Lawsuit - The lawsuit claims that Rocket Pharmaceuticals provided misleading information regarding the safety and clinical trial protocol of RP-A501 while concealing material adverse facts, including the known risks of serious adverse events [4]. - It is alleged that the company amended the trial protocol to include a new immunomodulatory agent without informing shareholders of this critical update [4]. - Following the announcement of a clinical hold by the FDA due to a serious adverse event resulting in a patient's death, the stock price of Rocket Pharmaceuticals fell significantly [5]. Legal Process - Investors who purchased Rocket Pharmaceuticals securities during the specified class period can seek appointment as lead plaintiff in the class action lawsuit, representing the interests of all class members [6]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone, and is recognized for securing significant monetary relief for investors [7].